INTRODUCTION
It is assumed that 8-16% of all epithelial ovarian cancer (EOC) cases is due to a BRCA1 or BRCA2 germline mutation. [1] [2] [3] [4] [5] For BRCA1 mutation carriers the cumulative lifetime risk of developing EOC up to the age of 70 is estimated to be 18-54%, and for BRCA2 mutation carriers 2.4-23%. 6, 7 . Both BRCA1-and BRCA2-associated ovarian cancers are mostly of serous histology (63-70%) and poorly differentiated (73-88%). 8 In previous studies, it has been observed that BRCA1/2-associated EOC patients have a longer progression-free survival (PFS) and overall survival (OS) compared to women with sporadic EOC. [9] [10] [11] [12] It is assumed that this is due to an increased sensitivity to DNA cross-linking agents such as platinum analogues, 10 since it has been shown that BRCA deficient cells have an impaired ability to repair DNA by means of homologous recombination. These effects might be intensified by treatment with poly(ADP-ribose) polymerase (PARP) inhibitors). 9, 13, 14 However, the early studies concerning BRCA1/2-associated EOC survival mainly included
Ashkenazi Jewish patients, did not provide data about chemosensitivity, were of small sample sizes, and survival of BRCA1 and BRCA2 mutation carriers was not separately analyzed. 9, [15] [16] [17] More recent data suggested a non-significantly longer PFS and OS in BRCA2-compared with BRCA1-associated EOC patients, while a high response to first-line chemotherapy was observed in both patient groups. 12, 18, 19 A more favorable OS of BRCA2-compared to BRCA1-associated EOC patients was recently confirmed in two other studies, 20, 21 both not evaluating response to chemotherapy, while Hyman et al. 21 compared small groups of patients including 45% of Ashkenazi Jewish ancestry. Therefore, in the current analyses, we further explored the clinicopathological characteristics and the results after primary treatment, including chemotherapy, PFS, treatment-free interval (TFI), and OS in a large nationwide cohort of BRCA1-versus BRCA2-associated EOC patients in the Netherlands.
METHODS STUDY POPULATION AND DESIGN
In this retrospective nationwide multicenter study, BRCA1-and BRCA2-associated EOC patients were identified through the databases of family cancer clinics (FCC) Response to chemotherapy was evaluated for all types of chemotherapeutic regimens together, and separately for the patients being treated with the combination platinum/paclitaxel, a platinum-based regimen (without paclitaxel), and nonplatinum-based chemotherapy. Differences in response rates between BRCA1 and BRCA2 mutation carriers were tested with the Pearson's Chi-square test. Cumulative survival (PFS, TFI, OS and OCSS) was calculated using the Kaplan-Meier method and survival differences between BRCA1 and BRCA2 mutation carriers were tested by using a logrank test. In addition, differences in PFS and OS between the two patient groups were examined in a univariate and multivariate Cox proportional hazard's model to estimate hazard ratios (HR) and 95%-confidence intervals (CIs), and to adjust for possible confounders including age at and year of diagnosis, FIGO stage, differentiation grade, histological type, CA125 level at diagnosis, residual tumor after debulking surgery (<1 cm or ≥1 cm) and type of chemotherapy.
Patients were censored in the analyses for PFS, OS and OCSS by date of last visit at the clinic or end date of this study (January 1 st , 2011). In the analyses for PFS and OCSS, patients were also censored by date of death due to other reasons than ovarian cancer. Statistical analyses were performed with SPSS 20.0 for Windows (SPSS, Chicago, IL, USA). A two-sided P-value less than 0.05 was considered statistically significant.
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RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Patient and tumor characteristics of the 245 BRCA1-and 99 BRCA2-associated EOC patients are listed in Table 1 . EOC was diagnosed at a younger age in BRCA1 compared with BRCA2 mutation carriers (median, 51.0 versus 55.5 years; P<0.001). Overall, 33% of all mutation carriers had a history of breast cancer preceding the EOC diagnosis, which again was diagnosed at a younger age in BRCA1 compared with BRCA2 mutation carriers (median, 43.3 versus 51.5 years) (P<0.001) ( Table 1 ). Other variables did not significantly differ between the two patient groups. EOC was generally diagnosed at advanced stage (FIGO-stage III or IV; 74%), was mainly poorly differentiated (73%), and of serous histology (64%). Median follow-up time was 5.0 years (range, 0.1-28.1) and 4.9 years (range, 0.3-28.7) in BRCA1 and BRCA2 mutation carriers, respectively. In total, 88% of the patients (BRCA1, 89%; BRCA2, 85%) had complete follow-up until date of death or end date of the study.
89% of the BRCA1 patients and 99% of the BRCA2 patients were proven mutation carriers; while 26 (11%) BRCA1 patients and 1 (1%) BRCA2 patient were not tested themselves but had at least one first-degree family member with a proven mutation (with a very high probability of being a mutation carrier as well).
PRIMARY TREATMENT OF EOC
The primary treatment of the majority of patients consisted of both surgery and chemotherapy (94%, Table 2 ). Residual tumor after primary and/or interval debulking surgery was not significantly different between BRCA1-and BRCA2-associated EOC patients; and was less than 1 cm in 80% (169/212) and 86% (70/81) of the BRCA1 and BRCA2 patients, respectively.
Chemotherapy generally consisted of a platinum-containing regimen, mostly in combination with paclitaxel, except for five BRCA1 mutation carriers who were treated with non-platinum-based chemotherapy (Table 2) . At the end of primary treatment, including chemotherapy, CR/NED was obtained in 86% of the BRCA1-versus 90% of the BRCA2-associated patients (P=0.36), while progressive disease (PD) during first-line chemotherapy was not observed in any of the BRCA2 patients, but in five (2%) BRCA1 patients (Table 2) .
Additionally, after stratifying for type of chemotherapy (platinum/paclitaxel, platinum-based without paclitaxel, and non-platinum-based), response to primary treatment was not significantly different in any of the subgroups between BRCA1-and BRCA2-associated EOC patients (Table 3) . 
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PFS, TFI, OS, AND OCSS
As shown in Figure 1 and Table 4 , the median PFS after primary treatment for EOC was significantly longer in BRCA2-compared with BRCA1-associated EOC patients, being 3.9 years (95%-CI 2.5-5.3) versus 2.2 years (95%-CI 1.9-2.5), respectively (P=0.006). At univariate analysis the hazard ratio (HR, BRCA2 versus BRCA1) for risk of progression was 0.65 (95%-CI 0.48-0.88), and at multivariate analyses 0.60 (95%-CI 0.43-0.83) both in favor of the BRCA2 group. Also in the left-truncated survival analysis (see methods section) BRCA2 mutation carriers still had a significantly longer PFS compared with BRCA1 mutation carriers (HR 0.58; 95%-CI 0.37-0.90; P=0.02; data not shown).
In addition, TFI after first line chemotherapy was significantly longer in BRCA2 than in BRCA1 patients (Table 4) . A TFI of more than six months (= chemotherapy-sensitive) was observed in 192 BRCA1-(86%) and in 77 (93%) BRCA2-associated EOC patients (P=0.11). In the left-truncated analysis, BRCA2 patients still had a longer TFI than BRCA1 patients (HR 0.61; 95%-CI 0.41-0.92; P=0.02; data not shown). Further, as shown in Figure 2a and Table 4 , the median OS was significantly longer in BRCA2-than in BRCA1-associated EOC patients, being 9.7 years (95%-CI 5.0-14.3) versus 6.0 years (95%-CI 5.1-6.9), respectively (P=0.04). The HR for the risk of death by univariate analysis was 0.70 favoring the BRCA2 group, and remained significant in the multivariate analysis (HR 0.67; 95%-CI 0.47-0.96) ( Table 4 ). In the left-truncated analysis, however, the OS was not significantly longer anymore for BRCA2 mutation carriers (HR 0.79; 95%-CI 0.53-1.17; P=0.24) (data not shown).
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Findings were comparable for OCSS ( Figure 2b and Table 4) , showing a significantly longer median OCSS in BRCA2 (10.4 years) compared to BRCA1 patients (6.3 years; P=0.02). 
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DISCUSSION
To our knowledge, this is the largest reported series of BRCA-associated EOC patients comparing both results of primary treatment, including chemotherapy, and survival between BRCA1 and BRCA2 patients. PFS and OS were significantly longer in BRCA2-compared with BRCA1-associated EOC patients, which could not be explained by differences in age at diagnosis, FIGO stage, differentiation grade, residual tumor after surgery, and type of chemotherapy. Importantly, PD during chemotherapy was not observed in BRCA2 patients, and treatment-free interval, as a surrogate for chemosensitivity, was significantly longer in BRCA2 than in BRCA1 patients. BRCA2 patients had a higher median age at diagnosis compared to BRCA1 patients (55.5 versus 51.0 years; P<0.001), which is consistent with other studies and reflects the same pattern as is seen in BRCA1 versus BRCA2 associated breast cancer, indicative of a differential penetrance in BRCA1 compared to BRCA2 mutation carriers. [18] [19] [20] Further, if older age would be a negative prognostic factor, one would expect a worse outcome for BRCA2 patients.
In our study cohort primary treatment consisted of both surgery and chemotherapy in 94% of patients enabling to evaluate response to chemotherapy. CR/NED was observed in 86% of BRCA1 and 90% of BRCA2 patients (P=0.36). PD was rarely observed; only five BRCA1 patients experienced PD and none of the BRCA2 patients. Of note, treatment-free interval, considered as a surrogate measure for chemosensitivity, was significantly longer in BRCA2 than in BRCA1 patients. While patient selection and definitions are not completely similar, our findings are in line with the results of Yang et al., 18 who published data of an observational study including 35 BRCA1-and 27 BRCA2-associated EOC patients describing a higher chemosensitivity rate in BRCA2 versus BRCA1 mutation carriers (100% versus 80%; P=0.05), and a longer platinum-free interval (18 versus 12.5 months). However, our BRCA series are much larger than their study cohorts, and for the TFI endpoint we did not exclude patients undergoing incomplete debulking surgery, which is known as a negative prognostic factor. 26 Other studies have not provided information regarding chemotherapy for BRCA1 and BRCA2 patients separately. Additionally, our study is the first that observed a significantly improved PFS after primary treatment of EOC in BRCA2 compared with BRCA1 patients, being 3.9 years (95%-CI 2.5-5.3) versus 2.2 years (95%-CI 1.9-2.5) respectively (P=0.006). Yang et al. 18 also found an improved PFS for BRCA2 versus BRCA1 reflecting a trend for significance (PFS rate at 3 years 44% versus 22%, P=0.05), whereas the study of Alsop et al. The mechanism behind the observed improved survival of BRCA2-compared with BRCA1-associated EOC patients remains unclear. It has been postulated that an improved life expectancy for BRCA2 compared with BRCA1 mutation carriers might be attributed to the biological characteristics of the tumors and a better response to cancer treatment. 9 Since in our study the results of debulking surgery were not different, as well as the response to chemotherapy was similarly high for both BRCA cohorts, the longer PFS in BRCA2 patients could not be explained by the response to primary treatment. However, the longer TFI observed in BRCA2, compared to BRCA1 patients, might reflect an improved sensitivity to chemotherapy of BRCA2 mutation carriers. We postulate that DNA repair after chemotherapy might be less efficient in BRCA2 compared to BRCA1 mutation carriers. Therefore, in our opinion, the improved PFS and OS in BRCA2 mutation carriers might be explained by a longer duration of response to chemotherapy, and could possibly be explained on a molecular biological level or underlying differences in tumor biology. Functionally, both BRCA1 and BRCA2 proteins were reported to play key roles in DNA damage repair, but appear to have distinct functions. BRCA1 plays a versatile role in tumor suppression through its ability to participate in DNA damage response, checkpoint control, mitotic spindle assembly, centrosome duplication and sister chromatid decatenation. BRCA2 has one main function in double-strand break repair by homologous recombination, namely by regulating the RAD51 protein. Also, it was suggested that BRCA2 mutations are more instable and that the promotor region is less often hypermethylated compared to BRCA1. 18 Overall, the mechanisms through which BRCA1 and BRCA2 mutations may result in different tumor biology require further research.
Strengths of our study are the consecutive series of BRCA1-and BRCA2-associated EOC patients, the large sample size of both BRCA cohorts, the availability of detailed clinical information including debulking status and type of chemotherapy for most patients, the long follow-up period, and the evaluation of PFS, TFI, OS, OCSS as well as response to chemotherapy. However, we are aware that some limitations have to be considered as well.
We could not exclude survival bias in the BRCA1 and BRCA2 cohorts potentially occurring by preferably selecting long-living EOC patients who were referred for genetic testing a long time after the initial EOC diagnosis. To deal with this possible bias we performed lefttruncated survival analyses and observed that the longer PFS for BRCA2 mutation carriers persisted (HR 0.58; 95%-CI 0.37-0.90; P=0.02), although the OS did not reach statistical significance anymore (HR 0.79; 95%-CI 0.53-1.17; P=0.24).
Nonetheless, the finding of a survival benefit for BRCA2-compared with BRCA1-associated EOC patients is obvious, and in line with other observations, and may have several clinical implications. Primarily, EOC patients with a BRCA1 or BRCA2 mutation may be informed more accurately about the expected survival and chemosensitivity. Furthermore, the improved survival of BRCA2 compared with BRCA1 mutation carriers may have implications for future clinical trial designs, since a substantial part (16-21%) of the patients with high-grade 53 serous ovarian carcinomas have a BRCA1/2 mutation. 5 Further, trials examining agents that target homologous recombination should particularly stratify for BRCA1 versus BRCA2 mutation status. This is also of importance for the currently ongoing phase 1 and phase 2 trials concerning PARP inhibitors showing anti-tumor activity especially in EOC patients with BRCA1/2 mutations. [28] [29] [30] [31] Our results indicate that the specific mutation status should be taken into account in the results analyses. Additionally, our observations and these of others underscore that it is important to perform genetic testing at EOC diagnosis, since this may have implications for counseling and therapy.
In conclusion, we found a significantly longer PFS, TFI and OS in BRCA2-compared with BRCA1-associated EOC patients. These data are of importance for both counseling and therapy of BRCA-associated EOC patients, and indicate that genetic testing in EOC patients is important. Also, in upcoming studies concerning the efficacy of new chemotherapeutic modalities or PARP inhibitors stratification for BRCA1 and BRCA2 mutation status should be incorporated.
